Interest in regenerative biologic therapies is growing in interventional pain medicine, which is driven by limitations of steroids and ablative procedures, as well as a focus on treating the main root cause. Different treatments like amniotic products, platelet-rich plasma, and mesenchymal stem cells are increasingly being used. Exosomes are small extracellular vesicles that carry bioactive molecules. These show promise in decreasing the inflammation as well as promoting tissue repair in preclinical studies. However, clinical evidence remains limited. Despite this, exosome products are already being marketed with misleading regulatory claims. The Food and Drug Administration (FDA) has issued warnings regarding unapproved exosome products. This gap between practice and highlights the need for ethical integration, clearer regulation, and stronger clinical data in patient care. This gap is well explained in a study published in Interventional Pain Medicine.
In the United States, exosome products are regulated by the FDA under human cells, tissues, and cellular and tissue-based products. They do not come under the section 361 products because of their biological activity, processing method, and non-homologous use. Hence, these are incorporated into section 351 biologics, which requires approval of a biologics license application (BLA) and an investigational new drug (IND) application. The US FDA has issued safety alerts and warning letters about misleading regulatory claims and unapproved medicinal products.
Internationally, South Korea’s Ministry of Food and Drug Safety (MFDS), the European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) regulators must apply strict standards which need good manufacturing practice (GMP), clinical evidence, and manufacturing. In clinical practice, legitimate use needs approval from the regulatory bodies; otherwise, exosome therapies remain not approved by the regulators, which results in risks of safety and legal issues.
Exosome therapies face significant challenges with their clinical and scientific information, which limits the routine use of these products in pain practice. Variability in the manufacturing process mainly impacts the consistency related to cell sources, culture conditions, and different isolation methods, which affects the composition of products. Standardized characterization exists, but reporting remains inconsistent, and no validated potency assays have been conducted that link dose to clinical effect. Clinically, optimal dosing, delivery methods, and safety profiles are unclear, particularly across various methods such as epidural or intradiscal injections. Furthermore, the evidence is limited to a few heterogeneous and small research studies that lack a robust study design. Compared to other biologic products, these exosomes remain in early development, which requires clinical trials and a standardized production method before reliable clinical application.
Exosome therapy raises marketing, economic, and ethical, as well as marketing, concerns in pain medicine. Many clinics promote unapproved treatments by using misleading claims such as “FDA registered” or “361 compliant,” which creates false perceptions of efficacy and safety. Patients may not fully understand the nature of these treatments, which leads to inadequate informed consent as well as autonomy. High out-of-pocket costs further exacerbate equity issues. Clinicians may face pressure to adopt emerging therapies despite limited evidence. Meanwhile, legitimate development needs costly GMP manufacturing and rigorous clinical trials. But lack of approved indications or reimbursement pathways. This gap between unregulated practice and regulated research delays progress and poses patient safety risks.
Clinicians must approach exosome therapy with strict adherence to transparency and regulations. In the U.S., lawful use requires an active institutional review board (IRB), IND approval, and a study sponsor; otherwise, exosome products remain unapproved biologics. Exosome therapy remains experimental, evidence is limited, and informed consent must clearly report the uncertainty and risks. Red flags include cash-only services, misleading FDA claims, and a lack of appropriate evidence. While promising, exosomes must currently be treated as investigational products that require regulatory compliance and rigorous clinical trials before routine clinical use.
Reference: Bourcier AJ, Kirkor ZM. Regulatory, ethical, and clinical barriers to exosome use in interventional pain medicine. Interv Pain Med. 2026;5(1):100746. doi:10.1016/j.inpm.2026.100746
